Investing Profile

Dan Becker

InvestorVC
Managing Director at Access Biotechnology
accessbio-tech.comNew York, New York
Photo of Dan Becker, Managing Director at Access Biotechnology
Your Intro Paths to Dan Becker

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →

Find Dan Becker on

cb
Current Investing Position
Access Biotechnology Managing Director
Investment Range
$100K - $5.0M
Sweet Spot
$1.5M
Investments On Record
15

Dan Becker is on these Sector & Stage Rankings

Dan Becker's Investments On Record (11)

CompanyStageDateRound SizeTotal Raised
Hemab
Series COct 2025$160M
Series BFeb 2023$140M
$290M
Co-investors: Uya Chuluunbaatar (Amzak Health Investors), Christine Borowski (Access Biotechnology), Joseph Anderson (Soffinova Partners)
Day One Biopharmaceuticals
Post Ipo EquityJul 2024$180M
Series BFeb 2021$130M
Series AMay 2020$60M
$370M
Co-investors: Julie Grant (Canaan Partners), Michael Gladstone (Atlas Venture), Derek DiRocco (RA Capital)
GRO Biosciences
Series BJul 2024$60M
$91M
Co-investors: Ameena El-Bibany (Artis Ventures (AV)), Russ Wilcox (Pillar VC), Geoffrey Smith (Digitalis Ventures), Dror Berman (Innovation Endeavors), Kevin Bitterman (Atlas Venture)
Mariana Oncology
Series BSep 2023$180M
Series ADec 2021$75M
$250M
Co-investors: Kevin Bitterman (Atlas Venture), Geert-Jan Mulder (Forbion), Josh Resnick
Zurp
Pre SeedJan 2023$5M
$5M
Co-investors: Amy Wu (Menlo Ventures), Daniel Darling (Darling Ventures), Niklas Jansen (Headstart Ventures), Julia Lipton (Awesome People Ventures), Lenny Rachitsky (Self-employed), Pascal Unger (Darling Ventures), David Weisburd (10X Capital), Siqi Chen (Invesco Private Capital), Dhani Jones (QEY Capital), Bobby Goodlatte (Notable Capital (formerly GGV Capital)), Scott Belsky (A24), Baron Davis, Nik Sharma, Shane Neman
Matchpoint Therapeutics
Series AOct 2022$70M
$100M
Co-investors: Bruce Booth (Atlas Venture), Jason P. Hafler (Sanofi Ventures)
ACELYRIN
Series CSep 2022$300M
$560M
Co-investors: Beth Seidenberg (Kleiner Perkins), Richard Gaster (venBio), Sean Harper
Curie Therapeutics
Series ADec 2021$75M
$75M
Co-investors: Kevin Bitterman (Atlas Venture)